SCHEMBL5111832

SCHEMBL5111832

CCOc1nc(NCc2c(F)cc(Cl)cc2F)nc2ccc(-c3ccc(F)cc3)nc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.36
TP53 P04637 2/20 0.36
ADORA2A P29274 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
KMT2A Q03164 2/20 0.35
MAP4K4 O95819 2/20 0.34
SGK1 O00141 2/20 0.34
SCN9A Q15858 1/20 0.34
TRPV3 Q8NET8 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.31
NAMPT P43490 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TOP1 P11387 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
NTRK1 P04629 1/20 0.31
CLK1 P49759 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5116366 0.93 MAP4K4 (0.36) MAPTTP53ADORA2ATDP1MAP4K4
SCHEMBL5123178 0.89 MAPT (0.40) MAPTTP53ADORA2AKDM4EMEN1
SCHEMBL5116226 0.88 NTRK1 (0.42) MAPTTP53ADORA2ATDP1KDM4E
SCHEMBL5114865 0.86 MAPT (0.41) MAPTTP53ADORA2ATDP1SMN1; SMN2
SCHEMBL5111887 0.85 MAPT (0.39) MAPTTP53ADORA2ATDP1MAP4K4
SCHEMBL5116008 0.84 MAPT (0.41) MAPTTP53ADORA2ATDP1MEN1
SCHEMBL5110852 0.84 DYRK1A (0.40) MAPTTP53ADORA2ATDP1SMN1; SMN2
SCHEMBL5123850 0.84 MAPT (0.43) MAPTTP53ADORA2ATDP1KDM4E
SCHEMBL5116297 0.84 ARNT (0.39) MAPTTP53ADORA2ATDP1MEN1
SCHEMBL4573278 0.84 MAP4K4 (0.42) MAPTMEN1ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US disclosed
WO-2008077651-A1 PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, DPYD, PNP MAPT 3290/4885TP53 1223/4885ADORA2A 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.